Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

Rhea-AI Summary

Belite Bio, a clinical-stage biopharmaceutical company (NASDAQ: BLTE) focusing on novel therapeutics for degenerative retinal diseases, has announced its participation in the Maxim Group 2024 Healthcare Virtual Summit. Dr. Hendrik P.N. Scholl, the company's Chief Medical Officer, will be part of the 'Ocular Drug Development' panel discussion.

The event is scheduled for Tuesday, October 15, 2024, at 11:00 am ET. Interested parties can access the live panel discussion through Maxim's M-Vest website. For registration and additional information, visitors are directed to https://m-vest.com/events/healthcare-10152024.

This participation underscores Belite Bio's commitment to advancing treatments for unmet medical needs in the field of degenerative retinal diseases.

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Hendrik P.N. Scholl, MD, MA, Chief Medical Officer of Belite Bio, will participate in the “Ocular Drug Development” panel discussion at the Maxim Group 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 11:00 am ET.

The live panel discussion can be accessed on Maxim’s M-Vest website. For more information and to sign up, please visit: https://m-vest.com/events/healthcare-10152024.

About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com

FAQ

When is Belite Bio (BLTE) participating in the Maxim Group 2024 Healthcare Virtual Summit?

Belite Bio (BLTE) is participating in the Maxim Group 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 11:00 am ET.

Who will represent Belite Bio (BLTE) at the Maxim Group 2024 Healthcare Virtual Summit?

Dr. Hendrik P.N. Scholl, Chief Medical Officer of Belite Bio (BLTE), will represent the company at the summit, participating in the 'Ocular Drug Development' panel discussion.

What is the focus of Belite Bio's (BLTE) drug development efforts?

Belite Bio (BLTE) focuses on developing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs.

How can interested parties access the Belite Bio (BLTE) panel discussion at the Maxim Group summit?

The live panel discussion can be accessed on Maxim's M-Vest website. Interested parties should visit https://m-vest.com/events/healthcare-10152024 for more information and to sign up.